CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
对 CAR-T 细胞在实体瘤中功能受限的机制认识与潜在解决方案
英文原题：Mechanistic insights into the limited function of CAR-T cells in solid tumors and potential solutions.
查看英文原题
Mechanistic insights into the limited function of CAR-T cells in solid tumors and potential solutions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T（CAR-T）细胞疗法通过工程化改造细胞毒性T细胞，使其直接识别肿瘤抗原，在急性淋巴细胞白血病（ALL）和慢性淋巴细胞白血病（CLL）等血液系统癌症治疗中已显示出很高疗效。然而，该疗法用于实体瘤尚未取得同等成功。研究已发现若干限制CAR-T 细胞治疗实体瘤疗效的障碍，包括靶抗原选择困难、CAR-T 细胞浸润受到物理屏障阻碍，以及肿瘤组织中存在免疫抑制环境。本综述全面概述目前对CAR-T 细胞治疗实体瘤相关问题的认识及潜在应对策略。
展开英文摘要原文
Chimeric antigen receptor T (CAR-T) cell therapy, in which cytotoxic T cells are engineered to directly recognize tumor antigens, has been shown to be highly effective in the treatment of blood cancers such as acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).
However, its application to solid tumors has not been as successful. Investigations have identified several barriers to the efficacy of CAR-T cell therapy in solid tumors; these include difficulties in target antigen selection, a physical barrier to CAR-T cell infiltration, and an immune-inhibitory environment in tumor tissue. In this review, we present a comprehensive overview of the current understanding of the problems underlying CAR-T cell therapy for solid tumors and potential countermeasures.
论文信息
- 作者
- Kouro T、Sasada T、Imai K
- 第一作者单位
- Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan.; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan.. Electronic address: kouro.3v70h@kanagawa-pho.jp.Japan
- 通讯作者单位
- Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan.. Electronic address: kima-4211@g.ecc.u-tokyo.ac.jp.Japan
- 文献类型
- 综述
- 期刊
- International immunopharmacology2025 Aug 28
- 原文标识
- PubMed 40480008 · DOI 10.1016/j.intimp.2025.115010